Celyad Oncology (Celyad Oncology) Beta : N/A (As of Apr. 27, 2024)

Celyad Oncology Beta Chart

Celyad Oncology Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
Beta		Get a 7-Day Free Trial					2.39	1.05	1.58	1.33	1.42

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Beta	Get a 7-Day Free Trial															1.33	1.20	1.54	1.42	2.28

Competitive Comparison of Celyad Oncology's Beta

For the Biotechnology subindustry, Celyad Oncology's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Beta distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Beta falls into.

Celyad Oncology Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Celyad Oncology  (OTCPK:CYADY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Celyad Oncology Beta Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description